title: Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.
abstract: BACKGROUND
  Improved influenza vaccines are needed to reduce influenza-associated complications in older adults. The aim of this study was to identify the optimal formulation of adjuvanted seasonal influenza vaccine for use in elderly people.
  
  
  METHODS
  This observer-blind, randomized study assessed the optimal formulation of adjuvanted seasonal influenza vaccine based on immunogenicity and safety in participants aged ≥65 years. Participants were randomized (~200 per group) to receive one dose of non-adjuvanted vaccine or one of eight formulations of vaccine formulated with a squalene and tocopherol oil-in-water emulsion-based Adjuvant System (AS03(C), AS03(B) or AS03(A), with 2.97, 5.93 and 11.86 mg tocopherol, respectively) together with the immunostimulant monophosphoryl lipid A (MPL, doses of 0, 25 or 50 mg). Hemagglutination-inhibition (HI) antibody responses and T-cell responses were assessed on Day 0 and 21 days post-vaccination. The ratio of HI-based geometric mean titers in adjuvanted versus non-adjuvanted vaccine groups were calculated and the lower limit of the 90% confidence interval was transformed into a desirability index (a value between 0 and 1) in an experimental domain for each vaccine strain, and plotted in relation to the AS03 and MPL dose combination in the formulation. This model was used to assess the optimal formulation based on HI antibody titers. Reactogenicity and safety were also assessed. The immunogenicity and safety analyses were used to evaluate the optimal formulation of adjuvanted vaccine.
  
  
  RESULTS
  In the HI antibody-based model, an AS03 dose-response was evident; responses against the A/H1N1 and A/H3N2 strains were higher for all adjuvanted formulations versus non-adjuvanted vaccine, and for the AS03(A)-MPL25, AS03(B)-MPL25 and AS03(B)-MPL50 formulations against the B strain. Modelling using more stringent criteria (post hoc) showed a clear dose-range effect for the AS03 component against all strains, whereas MPL showed a limited effect. Higher T-cell responses for adjuvanted versus non-adjuvanted vaccine were observed for all except two formulations (AS03(C) and AS03(B)-MPL25). Reactogenicity increased with increasing AS03 dosage, and with MPL. No safety concerns were raised.
  
  
  CONCLUSIONS
  Five formulations containing AS03(A) or AS03(B) were identified as potential candidates to improve immune responses to influenza vaccination; AS03(B) without MPL showed the best balance between improved immunogenicity and acceptable reactogenicity.
  
  
  BACKGROUND
  This trial is registered at ClinicalTrials.gov, NCT00540592.
authors.affiliation: Vaccine Discovery and Development, GlaxoSmithKline Vaccines, Wavre, Belgium.
authors.forename: Hans C
authors.initials: HC
authors.lastname: Rümke
authors.forename: Jan Hendrik
authors.initials: JH
authors.lastname: Richardus
authors.forename: Lars
authors.initials: L
authors.lastname: Rombo
authors.forename: Karlis
authors.initials: K
authors.lastname: Pauksens
authors.forename: Georg
authors.initials: G
authors.lastname: Plaßmann
authors.forename: Christelle
authors.initials: C
authors.lastname: Durand
authors.forename: Jeanne-Marie
authors.initials: JM
authors.lastname: Devaster
authors.forename: Walthère
authors.initials: W
authors.lastname: Dewé
authors.forename: Lidia
authors.initials: L
authors.lastname: Oostvogels
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D018448:Models, Immunological
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines
references.citation: Vaccine. 2011 Jun 15;29(27):4453-9
references.pmid: 21527299
references.citation: Lancet Infect Dis. 2013 Jun;13(6):485-96
references.pmid: 23518156
references.citation: Expert Rev Vaccines. 2010 Oct;9(10):1135-41
references.pmid: 20923265
references.citation: Vaccine. 2006 Feb 20;24(8):1159-69
references.pmid: 16213065
references.citation: Am J Prev Med. 2006 Jul;31(1):72-9
references.pmid: 16777545
references.citation: Vaccine. 2008 Sep 12;26 Suppl 4:D41-4
references.pmid: 19230158
references.citation: J Infect Dis. 2012 Mar 1;205(5):733-44
references.pmid: 22315336
references.citation: Clin Infect Dis. 2010 Sep 15;51(6):668-77
references.pmid: 20687838
references.citation: J Virol. 1991 Nov;65(11):6071-6
references.pmid: 1920626
references.citation: Vaccine. 2010 Feb 17;28(7):1740-5
references.pmid: 20034605
references.citation: Expert Rev Vaccines. 2009 Apr;8(4):483-92
references.pmid: 19348563
references.citation: Expert Rev Vaccines. 2009 Mar;8(3):293-8
references.pmid: 19249971
references.citation: J Infect Dis. 2008 Sep 1;198(5):632-4
references.pmid: 18652548
references.citation: JAMA. 2003 Jan 8;289(2):179-86
references.pmid: 12517228
references.citation: Lancet. 2007 Aug 18;370(9587):580-9
references.pmid: 17707753
references.citation: Vaccine. 2002 Mar 15;20(13-14):1831-6
references.pmid: 11906772
references.citation: Vaccine. 2005 Jul 8;23 Suppl 1:S10-25
references.pmid: 15908062
references.citation: Semin Respir Crit Care Med. 2004 Feb;25(1):3-10
references.pmid: 16088444
references.citation: J Immunol. 2008 Apr 15;180(8):5402-12
references.pmid: 18390722
references.citation: Hum Vaccin Immunother. 2013 Jan;9(1):144-52
references.pmid: 23143775
references.citation: Emerg Infect Dis. 2008 Jan;14(1):121-8
references.pmid: 18258091
references.citation: J Infect Dis. 2011 Jun 15;203(12):1729-38
references.pmid: 21606531
references.citation: N Engl J Med. 2003 Apr 3;348(14):1322-32
references.pmid: 12672859
references.citation: Immunol Rev. 2006 Jun;211:8-22
references.pmid: 16824113
references.citation: Curr Opin Immunol. 2009 Feb;21(1):23-9
references.pmid: 19246182
references.citation: Expert Rev Vaccines. 2007 Oct;6(5):699-710
references.pmid: 17931151
references.citation: Expert Rev Vaccines. 2007 Oct;6(5):723-39
references.pmid: 17931153
references.citation: J Hyg (Lond). 1972 Dec;70(4):767-77
references.pmid: 4509641
references.citation: Vaccine. 2008 Dec 2;26(51):6630-8
references.pmid: 18845199
references.citation: JAMA. 2004 Sep 15;292(11):1333-40
references.pmid: 15367555
references.citation: N Engl J Med. 2007 Oct 4;357(14):1373-81
references.pmid: 17914038
references.citation: Expert Rev Vaccines. 2012 Mar;11(3):349-66
references.pmid: 22380826
references.citation: J Immunol. 2004 Mar 15;172(6):3437-46
references.pmid: 15004143
references.citation: Expert Rev Vaccines. 2009 May;8(5):593-606
references.pmid: 19397416
references.citation: Nat Immunol. 2006 May;7(5):449-55
references.pmid: 16622432
references.citation: Vaccine. 2011 Mar 16;29(13):2461-73
references.pmid: 21256188